![]() | |
| Names | |
|---|---|
| Preferred IUPAC name
N-[2-(Diethylamino)ethyl]-4-(methanesulfonamido)benzamide | |
| Identifiers | |
| |
3D model (JSmol)
|
|
| ChEMBL | |
| ChemSpider |
|
| MeSH | Sematilide |
PubChem CID
|
|
| UNII |
|
CompTox Dashboard (EPA)
|
|
| |
| |
| Properties | |
| C14H23N3O3S | |
| Molar mass | 313.42 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
Sematilide is an antiarrhythmic agent. It is the same structure as for procainamide, differing only by the placement of a mesyl sulfonamide moiety to the anilino nitrogen.
Synthesis

Sematilide can be synthesized from benzocaine (1).12 Reaction with mesyl chloride, followed by saponification and removal of the water from the reaction mixture, gives sodium 4-[(methylsulfonyl)amino]benzoate (2). Chlorination with thionyl chloride gives 4-[(methylsulfonyl)amino]benzoyl chloride. Amide formation with N,N-diethylethylenediamine (3) then concludes the synthesis of sematilide (4).
References
References
- Lumma, William C.; Wohl, Ronald A.; Davey, David D.; Argentieri, Thomas M.; Devita, Robert J.; Gomez, Robert P.; Jain, Vijay K.; Marisca, Anthony J.; Morgan, Thomas K.; Reiser, H. J. (1987). "Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents". Journal of Medicinal Chemistry. 30 (5): 755–758. doi:10.1021/jm00388a001. PMID 3572962.
- David D. Davey, William C. Lumma, Jr., Ronald A. Wohl, U.S. patent 4,544,654 (1985 to Schering A.G.)
